Evidence map›Paper›PMID 36483694›Full record

ReviewHuman reproduction open2022

Infertility prevalence and the methods of estimation from 1990 to 2021: a systematic review and meta-analysis.

C M Cox, M E Thoma, N Tchangalova, G Mburu, M J Bornstein, C L Johnson, J Kiarie

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Human reproduction open, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 293 papers, 19 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
293citing papers in PubMed, 19 pooled it
65.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06481696 naunknown statusnot on this mapstarted 2024, after this paper: background citation

Randomized, Placebo-controlled, Double-blind, Single-center Trial to Evaluate the Possible Action of Resveratrol in Improving the Outcomes of Controlled Ovarian Stimulation During the IVF/ICSI Cycles in Couples With Unexplained Infertility

TypeinterventionalSponsorAndros Day Surgery ClinicRan2024 to 2025Enrolled90ConditionsUnexplained InfertilityArmsResveratrol-based multivitamin supplement, Folic acid, IVF/ICSI, Follitropin Alfa, Ganirelix Acetate 0.5 MG/ML [Fyremadel]
NCT07611448 enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

An Observational Study of Artificial Intelligence-Assisted Blastocyst Morphokinetic Analysis Using Short-Duration Video and Its Association With Pregnancy Outcomes

Typeobservational_patient_registrySponsorViable BiosciencesRan2026 to 2029Enrolled1,000ConditionsInfertility Assisted Reproductive Technology, Infertility (IVF Patients)
3 · Its place in the literature

Who cites it

293 citing papers in PubMed, 19 syntheses or guidelines pooled it, 400 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Pooled it
  20. The new WHO infertility guideline: A universal right to equitable, evidence-based fertility care.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article

233 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 5 institutions in 2 countries.

C M CoxIndependent Consultant, Shoreview, MN, USA.ORCID https://orcid.org/0000-0003-0270-029X
M E ThomaDepartment of Family Science, School of Public Health, University of Maryland, College Park, MD, USA.ORCID https://orcid.org/0000-0001-9267-4384
N TchangalovaResearch, Teaching, and Learning, STEM Library, University of Maryland Libraries, College Park, MD, USA.ORCID https://orcid.org/0000-0002-8491-6205
G MburuDepartment of Sexual and Reproductive Health and Research (SRH), World Health Organization, Geneva, Switzerland.ORCID https://orcid.org/0000-0002-5812-0529
M J BornsteinDivision of Epidemiology, Ohio State University, Columbus, OH, USA.ORCID https://orcid.org/0000-0002-5200-8181
C L JohnsonDepartment of Epidemiology and Community Health, School of Public Health, University of Minnesota, Minneapolis, MN, USA.ORCID https://orcid.org/0000-0003-4283-7418
J KiarieDepartment of Sexual and Reproductive Health and Research (SRH), World Health Organization, Geneva, Switzerland.ORCID https://orcid.org/0000-0003-4180-7858
University of Maryland, College Park · USWorld Health Organization · CHThe Ohio State University · USTSI (United States) · USUniversity of Minnesota · US

Funding

Scientific and Technical CoreP2CHD041022 · NICHD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI HIRAM BELTRAN-SANCHEZ · 2016 to 2026
$6.9M
NICHD NIH HHS P2C HD041022World Health Organization 001
6 · The paper itself

Abstract

study questionWhat is the contemporary prevalence of infertility in world populations and how do they differ by methodological and study characteristics? SUMMARY ANSWER: Pooled estimates of lifetime and period prevalence of 12-month infertility were 17.5% and 12.6%, respectively, but this varied by study population and methodological approach. WHAT IS KNOWN ALREADY: Infertility affects millions of individuals worldwide. Accurate measures of its magnitude are needed to effectively address and manage the condition. There are distinct challenges and variation in how infertility is defined and measured, limiting comparability of estimates across studies. Further research is needed to understand whether and how differences in methodological approaches and study characteristics account for heterogeneity in estimates. STUDY DESIGN SIZE DURATION: We conducted a systematic review and meta-analysis. Six electronic databases, websites of relevant organizations, and conference proceedings were systematically searched. Searches were limited to those published between 1 January 1990 and 11 March 2021, with no language restrictions. PARTICIPANTS/MATERIALS SETTING

methodsDescriptive and random-effects meta-analysis models were used to examine range of estimates and generate estimates of pooled lifetime and period prevalence of 12-month infertility, respectively, among representative populations. Meta-regression using restricted maximum likelihood was applied to account for definitional and study characteristics and to obtain adjusted estimates. Risk of bias was assessed with a validated tool. MAIN RESULTS AND THE ROLE OF CHANCE: The search yielded 12 241 unique records of which 133 studies met the criteria for the systematic review. There were 65 and 69 studies that provided data for lifetime and period prevalence of 12-month infertility, respectively. Five methodological approaches were identified: prospective time-to-pregnancy (TTP) design, current duration design, retrospective TTP design, self-reported infertility measure and constructed infertility measure. Ranges for lifetime (3.3-39.7%) and period estimates (1.6-34.0%) were similar and wide even after accounting for methodological and study characteristics. Pooled estimates of lifetime and period prevalence were 17.5% (95% CI: 15.0, 20.3, n = 37 studies, LIMITATIONS REASONS FOR CAUTION: Pooled estimates generated from meta-analysis were derived from 12-month infertility prevalence estimates that were heterogeneous across different domains, even after adjusting for definitional and study characteristics. The number of studies was small for certain strata from which pooled estimates were derived (e.g. there were only two studies for lifetime prevalence in Africa). WIDER IMPLICATIONS OF THE

findingsWhile findings show a high prevalence of infertility globally and regionally, it also reveals variation in measures to ascertain and compare infertility prevalence. More systematic and comprehensive collection of data using a consistent definition is needed to improve infertility prevalence estimates at global, regional and country-levels. STUDY FUNDING/COMPETING INTERESTS: This work was supported by the World Health Organization. The authors have no conflicts of interest. REGISTRATION NUMBER: PROSPERO CRD42020211704.

Indexed as

infecundityinfertilitysubfecunditysubfertilitytime-to-pregnancy

Identifiers

PMID36483694
PMCPMC9725182
OpenAlexW4308825553

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.